TSX:CRONPharmaceuticals
Cronos Group (TSX:CRON): Is Federal Cannabis Policy Hype Pushing the Stock Beyond Its Valuation?
The latest buzz around Cronos Group (TSX:CRON) is tied to growing speculation that U.S. federal policy on cannabis could soften, with talk of reclassifying marijuana reshaping sentiment across the entire sector.
See our latest analysis for Cronos Group.
That backdrop has helped Cronos Group’s share price climb 42.18 percent year to date, while a 53.68 percent total shareholder return over the past year suggests momentum is building as investors reassess the company’s growth and risk...